ISSN: 2381-8727

Journal international de l'inflammation, du cancer et de la thérapie intégrative

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

A Digital Patient-Input Tool that Combines Family Cancer History Screening and Newly Diagnosed Diabetes can be Used to Identify Those Who are at High Risk for Developing Pancreatic Cancer

Clatte F

The ability to enroll in pancreatic surveillance programs would be made possible by the collection of family history information, which could be a useful tool for identifying individuals who are more likely to develop pancreatic cancer. Weight loss and newly diagnosed diabetes may also be used as an early indicator of pancreatic cancer [1]. Combining family history and the Enriching New-Onset Diabetes for Pancreatic Cancer (ENDPAC) model to identify people who  might benefit from pancreatic surveillance is the focus of this study. The ENDPAC model's criteria were combined with questions about family cancer history in a novel questionnaire and digital input tool. The high-risk pancreatic clinic enrolled individuals who met the ENDPAC criteria directly [2 ]. A genetic counselor was recommended to those who met the criteria for a significant family history of cancer. 453 patients completed the questionnaire. 25.8% (117/453) of those had significant risk factors in their families [3]. Five of the 18 people (15.4%) who had previously undergone genetic testing had a pathogenic variant. Out of 117 people who were identified by the questionnaire as having a
significant family history, 34 (29.9%) underwent genetic testing. A pathogenic variant was present in four (11.8 percent) of these patients. Furthermore, through overflow family testing, two kin were found to convey pathogenic variations. From the 453 patients, four (0.9 percent) met the ENDPAC criteria. Two of them had pancreatic cancer, and the other two had signed up for the surveillance program. In conclusion, the ENDPAC model and family history screening can be combined to identify people at high risk for pancreatic cancer and make it easier to refer them to genetic counseling
and high-risk clinics [4 ].